Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation
N
Shared by NobleBlocks on Jan 1, 2001 • 12:00 AM UTC
Authors:
P. Colombat
Finding related papers...
Discussions
(0)
No comments yet
Be the first to share your thoughts!
Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation | NobleBlocks
